Stockscreener 앱 받기
71.23
1.06%
-0.76
시간 외 거래:
71.23
전일 마감가:
$71.99
열려 있는:
$71.35
하루 거래량:
219.22K
Relative Volume:
0.65
시가총액:
$1.64B
수익:
$923.71M
순이익/손실:
$84.68M
주가수익비율:
18.07
EPS:
3.9419
순현금흐름:
$182.81M
1주 성능:
-2.20%
1개월 성능:
-10.06%
6개월 성능:
-6.93%
1년 성능:
-25.80%
1일 변동 폭
$71.11
$72.06
1주일 범위
$71.11
$74.99
52주 변동 폭
$70.15
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(609) 759-1810
주소
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
71.23 | 1.78B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Virtus Advisers LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI (ANIP): Rises 1.37% to $77.92 for the Current Session; Boundary Watch: $74.02 and $81.82 Define the Nearby Reference Levels for the Current SessionHigh Dividend Factor - Vinanet
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Shift Sentiment? - Kalkine Media
Rice Hall James & Associates LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript - AOL.com
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold - Sahm
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares - GuruFocus
ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan - Kalkine Media
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan - Stock Titan
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com - Investing.com Australia
Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. - Investing.com
ANI Pharmaceuticals (ANIP) SVP, Generics Ori Gutwerg Sells 3,162 Shares - GuruFocus
ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474 - Bitget
ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77 - Stock Titan
ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration - Yahoo Finance
Analysts cut ANI Pharmaceuticals targets despite Q2 earnings beat - scanx.trade
Guggenheim cuts ANI Pharmaceuticals stock price target on Cortrophin guidance - Investing.com
Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00 - MarketBeat
Canaccord cuts ANI Pharmaceuticals stock price target on Cortrophin miss By Investing.com - Investing.com Canada
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Today Reveal? - Kalkine Media
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals (ANIP) Could Be 31% Undervalued On Strong Q2 Results And Guidance Reset - finance.yahoo.com
ANI Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ANIP) 2026-08-08 - Seeking Alpha
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results - MarketBeat
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance - webull.com
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside - TradingView
Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket - Investing.com
ANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underway - Investing.com Nigeria
ANI Pharmaceuticals Inc (ANIP) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
ANI Pharmaceuticals Announces Q2 2026 Earnings and Releases Updated Investor Presentation - Kalkine Media
ANI Pharmaceuticals, Inc (ANIP) Q2 2026 Earnings Call Transcript - AlphaStreet
ANI Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Guidance Signals Fresh Momentum - Kalkine Media
ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap DownHere's Why - marketbeat.com
ANI Pharmaceuticals Q2 Earnings Call Highlights - marketbeat.com
ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut - Yahoo Finance
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.66%
0.33%
자본화:
|
볼륨(24시간):